Logo

Koken Licenses Alnylam's RNAi Patents for Research Uses

Oct 28, 2009

NEW YORK (GenomeWeb News) – Tokyo-based Koken has acquired the rights to use Alnylam Pharmaceuticals' RNAi-related patents under a non-exclusive, worldwide agreement, Alnylam said today.

Koken will use the patents from Alnylam's Kreutzer Limmer patent family, which covers aspects of the structure and functional properties of synthetic RNAi products, to manufacture and offer siRNA reagents to industry and academic researchers.

Alnylam VP of Business Development Jason Rhodes said in a statement that the company currently has more than 15 license agreements with global research products suppliers, including five in Asia.

"Access to the Kreutzer-Limmer patent estate enables us to augment our current RNAi products, thereby strengthening our position in the life sciences marketplace," Koken President Yuzo Tarumia said.

Financial terms of the agreement were not released.

Filed under

Gene Editing, Gene Silencing, & CRISPR
Business News
intellectual property
licensing agreement
RNAi
Alnylam
Breaking News
The Scan

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.

Algorithm Teases Out Genetic Ancestry in Individuals at Biobank Scale

Researchers develop an algorithm known as Rye to tease apart ancestry fractions in admixed individuals at a biobank-scale, applying it to 488,221 UK Biobank participants in Nucleic Acids Research.

Multi-Ancestry Analysis Highlights Comparable Common Variants at Complex Trait-Linked Loci

Researchers in Nature Genetics examine common variants implicated in more than three dozen conditions, estimating genetic effect similarities across ancestry tracts in admixed individuals.

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.